NCT02649855 2024-08-06
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
8 trialsNCT01867333 2023-09-26
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02326805 2023-07-19
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
National Cancer Institute (NCI)
Phase 2 Completed
NCT02649439 2022-11-14
Prostvac in Patients With Biochemically Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01875250 2020-09-16
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01322490 2019-09-04
Prospect
Bavarian Nordic
Phase 3 Completed
NCT00060528 2017-10-26
Sequential Vaccinations in Prostate Cancer Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01145508 2017-09-19
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated